secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001854270-24-000081
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences shareholders approve officer exculpation and reverse stock split authorization (range 1:5 to 1:30)
--------------------------------------------------------------------------------

- Stockholders approved an officer exculpation amendment limiting liability of certain officers as permitted by Delaware law; effective July 10, 2024.
- Reverse stock split approved at ratio between 1:5 and 1:30, as determined by the Board; Board may abandon the split.
- KPMG LLP ratified as independent auditor for fiscal year ending Dec 31, 2024 (30,547,655 votes for, 63,495 against).
- Officer exculpation amendment and reverse split were Proposals 2 and 3; 68.97% of outstanding shares represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000081/0001854270-24-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000081/snti-20240710.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer